Actuate Therapeutics, Inc. (ACTU) company profile
Close on Nov 13, 2026Market cap $6.85MP/E –Yield –
About Actuate Therapeutics
Pharmaceutical Preparations, SIC 2834
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers by inhibiting glycogen synthase kinase-3 beta (GSK-3β). The company centers its research and development on its lead small-molecule product candidate, elraglusib, which functions by blocking signaling pathways essential for cancer cell survival and tumor growth while also regulating anti-tumor immunity. Actuate develops elraglusib across two primary delivery formulations, including an intravenous injection and an oral tablet. Its investigational treatments aim to address adult and pediatric patient populations facing complex oncological conditions such as metastatic pancreatic ductal adenocarcinoma, pediatric refractory solid tumors including Ewing sarcoma and neuroblastoma, metastatic melanoma, and colorectal cancer.
The company operates as a clinical-stage organization with clinical trials evaluating treatments in hundreds of patients. Actuate maintains principal executive offices in Fort Worth, Texas.
Summary of the business section of Actuate Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Actuate Therapeutics, Inc.
- Headquarters
- Fort Worth, TX
- Address
- 1751 River Run, Suite 400 76107
- Phone
- (847) 986-4190
- Website
- actuatetherapeutics.com
- Employees
- 12, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Crowe LLP, Costa Mesa, California
Stock & identifiers
- Ticker
- ACTU
- Exchange
- Nasdaq
- IPO date
- Aug 13, 2024
- Shares outstanding
- 24M, Aug 13, 2026
- Public float
- $42.10M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1652935
- CUSIP
- 005083100
- ISIN
- US0050831009
- FIGI
- BBG00NK7LK03
- Share class FIGI
- BBG00NK7LK12
- EIN
- 47-3044785
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Daniel M. Schmitt | President, CEO and Director | 1,073,300 |
| Andrew Paul Mazar | Chief Operating Officer | 127,250 |
| Paul J. Lytle | Chief Financial Officer | – |
| Kairos Venture Investments, LLC | Director | – |
| Kairos Venture Partners II, L.P. | Director | – |
| Kairos Venture Opportunities I, L.P. | Director | – |
| SPV Fund LLC Kairos | Director | – |
| Kairos-Actuate SPV, L.P. | Director | 2,487,474 |
| James T. Demetriades | Director | – |
| Todd S. Thomson | Director | 2,354,344 |
| BIOS Fund II NT, LP | Director | – |
| BIOS Fund I, LP | Director | – |
| BIOS Fund II, LP | Director | 10,257,429 |
| BIOS Fund I QP, LP | Director | – |
| BIOS Fund II QP, LP | Director | 9,147,214 |
| BIOS Fund III, LP | Director | – |
| BIOS Fund III QP, LP | Director | – |
| BIOS Fund III NT, LP | Director | – |
| Bios Clinical Opportunity Fund, LP | Director | 1,472,797 |
| BIOS Actuate Co-Invest II, LP | Director | – |
| Bios Actuate Co-Invest III, LP | Director | 231,377 |
| BIOS Actuate Co-Invest I, LP | Director | 10,196,456 |
| Bios 2024 Co-Invest, LP | Director | 125,000 |
| Aaron G.L. Fletcher | Director | – |
| Amy L. Ronneberg | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Option awards | Total | vs. prior year |
|---|---|---|---|---|---|
| Daniel M. Schmitt President and Chief Executive Officer | $570.00K | $142.33K | $1.45M | $2.17M | -61% |
| Andrew P. Mazar, Ph. D. Chief Operating Officer | $450.00K | $102.15K | $867.42K | $1.42M | +110% |
| Paul Lytle Chief Financial Officer | $435.36K | $79.06K | $491.94K | $1.01M | -47% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 13, 2024
- Securities offered
- 2,800,000
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Feb 9, 2025
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“we had 12 full-time employees plus a number of contract workers, who manage and oversee all aspects of our operations, including”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 30, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jul 17, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 19, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 13, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 20, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?